ADA: Novo Nordisk's Big Hopes For Victoza Follow-On's Weight Loss Benefits
Novo Nordisk AS's semaglutide has the potential to rule the GLP-1 space for treatment of type 2 diabetes because of its strong efficacy and greater effects on weight loss, Chief Medical Officer Alan Moses said during the 2016 American Diabetes Association annual conference, where the company reported updates from the ongoing Phase III SUSTAIN clinical trial program.
You may also be interested in...
A rush in the 2010s of high-tech and digital companies focused on women’s health and wellbeing are maturing, adding weight to the more traditional women's health market that has struggled to get attention from investors in the past.
An interactive look at recent executive-level company changes and promotions in the biopharma, medical device and diagnostics industries.
A selection of articles you might have missed from September 2020, including exclusive interviews with industry leaders and a review of value-based contract approaches in the US.